News By Tag
* DNA Diagnostics Market
* Product Types
* DNA Diagnostics Application
* DNA End user
* More Tags...
News By Place
DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research
The latest figures suggest that approximately 8.2 million people are living with cancer and 39 million with HIV. These numbers are set to increase consistently;
To View the complete report, visit the website at http://www.alliedmarketresearch.com/
AMR analysis suggests that the tremendous potential of novel DNA diagnostic technologies and the probability of them being adopted in personalized medicines has not only reduced the expenditure in diagnostic procedures but has also helped in increasing the efficiency of chronic disease identification. Furthermore, the emergence of personalized medicines and the rising number of initiatives vis-à-vis product development and clinical trials from key players has laid the groundwork for DNA diagnostics technologies. Various technologies such as PCR, sequencing technology, microarray, in situ hybridization and mass spectrometry are considered in this report, with special emphasis on key market trends and their growth potential. Given its wide scope of application in almost all activities related to DNA diagnostics, the polymerase chain reaction (PCR) technology holds the largest share of DNA diagnostics market revenue.
Market analysis in terms of geography suggests that developed economies would retain their dominance in the market. This could be attributed to the early adoption of the technology due to potential reduction offered by DNA diagnostic to their high healthcare expenditure. However, developing economies, such as in Asia-Pacific, will significantly influence the DNA diagnostic market during the extended forecast period (2020-2025), largely due to potential growth in per capita healthcare expenditure and very large undiagnosed population.
Several companies operating in this region are seeking novel technologies to gain traction in the competitive market. Product launch is the key strategy adopted by companies operating in this market. These companies are developing novel products for the treatment of various diseases such as infectious diseases, cancer, prenantal diagnosis, pre-implantation diagnostics and myogenic disorder. Additionally, these companies are also adopting collaboration and acquisition to retain their respective positions and to gain traction in the market. Key companies profiled in the report are Bayer Diagnostic, Sysmex, Roche Diagnostics, Abbott laboratories, Cephide, Gene-probe Inc., Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Johnson and Johnson, and Novartis.
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based inPortland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions". AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5320 SW Macadam Avenue,
Suite 100, Portland, OR 97239
Toll Free: +1(855)711-1555 (U.S. & Canada)